Physician profile
Jason Cobb
NPI 1407026818
$5,940.89
in general payments reported to CMS, 2019-2025
10 companies · $70.73 in 2025
The $70.73 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9.36 · 2020: $2,573 · 2021: $1,446 · 2022: $249 · 2023: $1,326 · 2024: $268 · 2025: $70.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,200 · Food and Beverage: $384 · Education: $79.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,200.00 |
| Food and Beverage | $384.43 |
| Education | $79.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,572.50 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $1,200.00 | 2023 | |
| Glaxosmithkline, LLC. | $920.00 | 2021 | |
| Travere Therapeutics, INC. | $479.63 | 2021-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $425.51 | 2021-2025 | Lupkynis |
| Ardelyx, INC. | $143.51 | 2024 | Ibsrela |
| Novo Nordisk INC | $134.56 | 2022 | |
| Calliditas Therapeutics US INC. | $55.82 | 2024 | |
| Akebia Therapeutics INC | $9.36 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Cobb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.